Biologics

COLUMBIA, Md., Oct. 30, 2018 (GLOBE NEWSWIRE) -- Osiris Therapeutics, Inc. (NASDAQ: OSIR), a regenerative medicine company focused on developing and marketing products for wound care, orthopedics, and sports medicine, will present advanced clinical and scientific research at the Symposium on Advanced Wound Care (SAWC) Fall Conference. A total of six studies (three clinical and

SAN DIEGO, Oct. 24, 2018 (GLOBE NEWSWIRE) -- Samumed announced today top-line data from its phase 2b trial of SM04690 in knee osteoarthritis (OA). Results showed that treatment with a single intra-articular injection of SM04690 demonstrated significant improvements in pain, function and patient global scores in two separate doses. Further details can be found here. Samumed’s

October 25, 2018 DURHAM, N.C.--(BUSINESS WIRE)--Bioventus, a global leader in orthobiologic solutions, today announced the appointment of Susan M. Stalnecker, former Vice President and Treasurer, E.I. du Pont de Nemours and Company, to the company’s Board of Managers, replacing Michael Minogue. “Susan is joining the Bioventus Board at an exciting time as we accelerate the growth of our

October 24, 2018 BEDFORD, Mass.--(BUSINESS WIRE)--Anika Therapeutics, Inc. (NASDAQ: ANIK) (“Anika” or the “Company”), a global, integrated orthopedic and regenerative medicines company specializing in therapeutics based on its proprietary hyaluronic acid (“HA”) technology, announced that, effective immediately, Anika’s Board of Directors has appointed Susan Vogt as an independent director. Ms. Vogt most recently served as Chief Executive

October 23, 2018 PRINCETON, N.J. & OR AKIVA, Israel--(BUSINESS WIRE)--Regentis Biomaterials today announced it has expanded the SAGE clinical trial of GelrinC™ for the treatment of articular cartilage damage in the knee to 11 U.S. sites. GelrinC is an investigational device being evaluated as a treatment to help the body regrow cartilage in the knee. Articular cartilage

SCHLIEREN (ZURICH), Switzerland, Oct. 18, 2018 (GLOBE NEWSWIRE) -- Kuros Biosciences AG (SIX: KURN) announced today that the Company has reached a key milestone in its Fibrin-PTH (KUR-113) spinal fusion product candidate development program with the submission of a 510(k) regulatory package for its enabling lumbar intervertebral body fusion device to the U.S. Food and Drug

Gosselies, Belgium, 17 October 2018, 6 pm CEST – BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the bone cell therapy company addressing high unmet medical needs in orthopaedics and bone diseases, today announces results of the first efficacy study of the Company’s enhanced viscosupplement, JTA-004, in patients with moderate symptomatic knee osteoarthritis, supporting future clinical development

HOUSTON, Oct. 11, 2018 /PRNewswire/ -- SpinalCyte, LLC, a Texas-based regenerative medicine company focused on regrowth of the spinal disc using Human Dermal Fibroblasts, today announced the publication of results from its study on using cell transplantation as a cell therapy for disc degeneration. The article titled "Therapeutic Effects of Cell Therapy with Neonatal Human Dermal Fibroblasts and

DALLAS, Oct. 2, 2018 /PRNewswire/ -- Bone Solutions Inc. (BSI), an ortho-biologics technology company announces the first 250 cases of implanted OsteoCrete®.  OsteoCrete® is a Magnesium-based bone void filler is designed to assist with bone repair and generation, and it's the first in the U.S. to incorporate magnesium, a critical property for bone health and development. "In our